Microencapsulated tumor organoids maintain drug sensitivity stratification.

Authors

Aarthi Namasivayam, Alica K Michels, Christopher J Halbrook, Elliot E Hui

Published in

Lab on a chip. Sep 25, 2026. Epub Sep 25, 2026.

Abstract

Drug sensitivity profiling on patient-derived organoids mirrors patient response for gastrointestinal cancers and is currently being evaluated in clinical trials to guide treatment decisions. However, long expansion times are typically required to achieve adequate cell numbers. Accordingly, miniaturization of organoid cultures can be leveraged to reduce assay time and increase the number of compounds tested. Microencapsulation by droplet microfluidics has been applied to produce miniaturized organoid cultures, but the predictive accuracy has yet to be fully established. Here, we show that drug response can be preserved while reducing pancreatic cancer organoid culture volume by 100-fold. Testing five standard-of-care chemotherapeutics in miniaturized 0.5 μL cultures versus standard 50 μL cultures, we find that rank-ordering by drug sensitivity produced near identical stratification. Overall, these data demonstrate the potential for platforms based on this strategy to accurately pharmacotype tumor biopsies while reducing the time needed to inform treatment.

PMID:
42831367
Bibliographic data and abstract were imported from PubMed on 05 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.